If GTC is increasing the herd, this would lend creedence to the fact that the results have not gone horribly wrong. I must say I am curious to the results of Merrimack's results. I would expect to hear results by at least the 1st of the year, since you say this is their cash raising season.
Some other things I have wondered is: Why if they already have alpha-1-antitrypsin being produced in sufficient quantities, then why would it take several years to even develop a phase I study?
Relatively speaking, is albumin at a price level that is somewhat affordable that GTC does not find this as profitable venture to pursue?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.